KAN0439834

inhibitor of ROR1 receptor tyrosine kinase

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2018 - "KAN0439834 was much more effective in inducing tumor cell death than the ROR1 mAb although both inhibited ROR1 phosphorylation and downstream non-canonical Wnt pathway molecules. " 01/01/2018 - "KAN0439834 induced significant apoptosis of the tumor cells. " 01/01/2018 - "Combination of KAN0439834 with erlotinib or ibrutinib had significant additive effects on tumor cell death. "
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/01/2018 - "First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells."

1.	Receptor Tyrosine Kinase-like Orphan Receptors
2.	Erlotinib Hydrochloride (CP 358,774)
3.	ibrutinib